announced Wednesday morning that it has successfully completed clinical trials for its vaccine in children as young as six months old - and it will soon submit data to federal regulators to get the shot approved. The Phase 2 and 3 trials were recently completed and included the six months to two years old age group, and the two to six years old groups. Both received two 25 microgram vaccine doses.The Cambridge, Massachusetts-based company hopes to have its shot available for young children as early as this summer.
Load More
Load More